Pond Technologies

VOYAGEUR PHARMACEUTICALS (OTCMKTS: VYYRF) STOCK QUOTE

Last Trade: US$0.08
Volume: 0
5-Day Change: -1.00%
YTD Change: -1.00%
Market Cap: US$4.140M

LATEST NEWS FROM VOYAGEUR PHARMACEUTICALS

Voyageur Pharmaceuticals Ltd. ( TSXV:VM ) ( OTC :VYYRF) (the "Company" or "Voyageur") has submitted a notice of work with the BC Ministry of Mines ( BCMM ), for the removal of 2,000 tonnes of barite in 2023. Upon approval from the BCMM, this sample will be used for testing on a new active pharmaceutical ingredient ( API ) pilot plant, that is tentatively scheduled to begin construction in 2023. Voyageur will excavate small,... Read More
Calgary, Alberta – TheNewswire - August 15 th , 2022 : Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC :VYYRF) (the "Company" or "Voyageur") has appointed Albert Deslauriers as interim CFO. Al held several senior financial positions with the Lafarge Group over a 34 year career including Vice President of Finance for Lafarge Canada. Al has a financial and general management background with major public corporations including... Read More
Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC :VYYRF) (the " Company " or " Voyageur ") is pleased to announce that, further to its news releases dated May 26 and 31, 2022, it has completed its non-brokered private placement of units of the Company (" Units ") at a price of $0.10 per Unit, issuing 11,570,000 Units for aggregate gross proceeds of $1,157,000 (the " Offering "). Each Unit is comprised of one (1) common share ("... Read More
Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the " Company " or " Voyageur ") is pleased to announce that, further to its news release dated May 26, 2022, and due to strong investor demand for its recently announced non-brokered private placement of units of the Company (" Units ") at a price of $0.10 per Unit, it has increased the maximum size of the offering from 10,000,000 Units for gross proceeds of $1,000,000 to... Read More
Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the " Company " or " Voyageur ") is pleased to announce that it plans to complete a non-brokered private placement of up to 10,000,000 units (the " Units ") of Voyageur at a price of $0.10 per Unit for aggregate gross proceeds of up to $1,000,000 (the " Offering "). There is no minimum Offering. The Units will be comprised of one (1) common share (" Common Share ") and one... Read More
Voyageur Pharmaceuticals Ltd. (“ Voyageur ” or the “ Company ”) (TSXV:VM) is pleased to announce that it is progressing with its product development, regulatory pathway and material processing/manufacturing operations that could result in revenue generation in Canada this year and more importantly revenue generation in the United States early next year. Product Development As part of the product development process, Voyageur... Read More
Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the "Company" or "Voyageur") has agreed to pay deposits for work on design of the Company's manufacturing facility and pay other existing debts in an amount of up to $100,000 through the issuance of common shares of the Company ("Common Shares") at a deemed price per share of $0.11 based on the closing price of the Common Shares at the close of trading on May 10, 2022 (the... Read More
Voyageur Pharmaceuticals Ltd. (“ Voyageur ” or the “ Company ”) (TSXV:VM) (OTC:VYYRF) is pleased to announce the filing of its Preliminary Economic Assessment (“ PEA ”) for the development of its Frances Creek pharmaceutical barium sulfate project (the “ Project ”), located in British Columbia, Canada. The PEA was initially disclosed in a news release dated January 11, 2022 and was prepared by SGS Geological Services (“ SGS... Read More
Calgary, Alberta – TheNewswire - February 16, 2022 - Voyageur Pharmaceuticals Ltd. (“ Voyageur ” or the “ Company ”) (TSXV:VM) (OTC:VYYRF) is pleased to announce the completion of the NI 43-101 report, the Jubilee Mountain Property, authored by Craig Dunn, P.Geo, the effective date of February 4, 2022 (the " Report ") for the Jubilee Mountain copper polymetallic project (the " Jubilee Project "). In addition, Voyageur has... Read More
GreenStockNews
Voyageur Pharmaceuticals Ltd. (“ Voyageur ” or the “ Company ”) (TSXV:VM) is pleased to announce the results of its Preliminary Economic Assessment (“PEA”) for the development of its Frances Creek pharmaceutical barium sulfate project (the “Project”), located in British Columbia, Canada. The PEA was prepared by SGS Geological... Read More
Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC : VYYRF) (the "Company" or "Voyageur") has a preliminary economic assessment (PEA) on its Frances Creek project pending with SGS Canada, who have stated the first draft will be completed by mid December. There have been delays outside of management's control. Building out the mining operation and product manufacturing represents the second phase of Voyageur’s plan. Voyageur is... Read More
Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC : VYYRF) (the "Company" or "Voyageur") is pleased to announce the signing of a non-binding Memorandum of Understanding (“MOU”) with Summit Nanotech Corporation (“SNT”). The MOU proposes an agreement between Voyageur and SNT to develop a more sustainable process for the production of iodine medical products, that are used as contrast agents. The process will be developed by... Read More
Voyageur Pharmaceuticals Ltd. (TSXV: VM) ( OTC :VYYRF) (the "Company" or "Voyageur") develops, manufactures and will commercialize high-performance cost-effective imaging contrast agents for the medical radiology marketplace. Today the Company announced the completion of the formation of its Scientific Advisory Board (SAB), with the additions of two leading doctors in the radiology industry. The SAB is to support the firm’s... Read More
Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC: VYYRF) (the "Company" or "Voyageur") develops, manufactures and will commercialize high-performance cost effective imaging contrast agents for the medical radiology marketplace. Today the Company announced the formation of its Scientific Advisory Board (SAB) to support the firm’s research, clinical and product development programs. The SAB is to provide our management team, BOD... Read More
Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC :VYYRF) (the "Company" or "Voyageur") has been working with SGS Canada Inc. on the Preliminary Economic Assessment (PEA) for its Frances Creek barium Quarry operation. A critical part of the PEA is the design of an upgrading system to process the Frances Creek barium concentrate to meet the requirements of the United States Pharmacopeia (USP). The upgrading process has been the... Read More
Calgary, Alberta – TheNewswire - August 12, 2021 – Voyageur Pharmaceuticals Ltd. ( TSXV : VM ) USA (OTC : VYYRF) (the "Company" or "Voyageur") announced that it has issued 200,000 options to directors pursuant to its incentive stock option plan (the “Options”). In addition, the Company announces it has issued 169,872 Deferred Share Units (“DSU’S”) to directors pursuant to its equity incentive compensation plan. The grants... Read More
Calgary, Alberta - TheNewswire - July 26 th , 2021 - Voyageur Pharmaceuticals Ltd . (TSXV : VM) (OTC:VYYRF) (the “Company” or “Voyageur”). Voyageur is very pleased to announce that Frank Wright and Ralph Hesje are being appointed to the Voyageur Board as Director’s effective immediately. Voyageur is committed to create a strong independent board of directors with extensive experience in board management, business... Read More
Voyageur Pharmaceuticals Ltd. ( TSXV:VM) ( OTC:VYYRF ) (the "Company" or "Voyageur") announces that, further to news releases dated April 13 and 23, and May 5 and 28, 2021, Voyageur has closed its financing and will not be proceeding with a third and final tranche of its non-brokered private placement of common units ("Common Units") and flow-through units ("Flow-Through Units") (the "Offering"). Pursuant to the Offering,... Read More
Voyageur Pharmaceuticals Ltd. ( TSX.V:VM) ( OTC:VYYRF ) (the "Company" or "Voyageur") announces that, further to news releases dated April 13 and 23, 2021 and May 5, 2021, it has closed the second tranche of a non-brokered private placement of common units ("Common Units") and flow-through units ("Flow-Through Units") (the "Offering"). The Offering is a combination of (i) Common Units issued at a price of $0.15 per Common... Read More
Voyageur Pharmaceuticals Ltd. ( TSX.V:VM) ( OTC:VYYRF ) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada (HC) for its fifth product, MultiXthick barium sulfate suspension that contains 105% w/v barium sulfate suspension for oral and rectal administration of the gastrointestinal tract. Voyageur has built a full suite of barium radiographic contrast media products for global... Read More
Voyageur Pharmaceuticals Ltd. ( TSXV:VM) ( OTC:VYYRF ) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada (HC) for its fifth product, MultiXthick barium sulfate suspension that contains 105% w/v barium sulfate suspension for oral and rectal administration of the gastrointestinal tract. Voyageur has built a full suite of barium radiographic contrast media products for global... Read More
Voyageur Pharmaceuticals Ltd. ( TSXV:VM) ( OTC:VYYRF ) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada (HC) for its product, MultiXthin barium sulfate suspension . MultiXthin is specifically designed for single contrast radiographic examinations of the oesophagus, stomach, and small bowel to visualize the gastrointestinal (GI) tract in adult and pediatric patients.... Read More
Voyageur Pharmaceuticals Ltd. ( TSX.V:VM) ( OTC:VYYRF ) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada (HC) for its product, MultiXthin barium sulfate suspension . MultiXthin is specifically designed for single contrast radiographic examinations of the oesophagus, stomach, and small bowel to visualize the gastrointestinal (GI) tract in adult and pediatric patients.... Read More
Voyageur Pharmaceuticals Ltd. ( TSXV : VM ) ( OTC : VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has increased the previously announced non-brokered offering of units (the "Offering") from a maximum of $1,725,000 to $2,100,000. Further to the news release of the Company dated April 13 th , 2021, the Offering was a combination of Pricing as follows: A "Common Unit" priced at $0.15 where each Common Unit... Read More
Voyageur Pharmaceuticals Ltd. ( TSX.V : VM ) USA (OTC : VYYRF) (the “Company” or “Voyageur”), is pleased to announce that the D.C. Circuit Court of Appeals has upheld a prior ruling that conclude d radiographic contrast agent barium sulfate, qualifies as a device rather than a drug. This ruling has a significant impact on Voyageur’s planned product roll out into the United States (US). Management of Voyageur estimates that... Read More
Voyageur Pharmaceuticals Ltd. ( TSXV : VM ) USA (OTC : VYYRF) (the “Company” or “Voyageur”), is pleased to announce a proposed non-brokered private placement financing of up to 11,500,000 units, for gross proceeds of up to $1,725,000 (the "Offering"). Under the Offering, the Company expects to raise up to $1,500,000, but has approved up to $1,725,000 to give the Company an option to increase the Offering by up to 15% to... Read More
Voyageur Pharmaceuticals Ltd. ( TSX.V:VM) ( OTC:VYYRF ) (the "Company" or "Voyageur") announced that is has issued 2,625,000 options to directors, officers and consultants pursuant to its incentive stock option plan (the "Options"). On March 29, 2021, the Company's board of directors approved the grant of Options, to be effective on April 1, 2021 using the closing price on that day. The Options were issued with an exercise... Read More
Voyageur Pharmaceuticals Ltd. ( TSX.V:VM) ( OTC :VYYRF ) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada (HC) for its product, MultiX barium sulfate powder. MultiX is specifically designed for oral suspension and indicated for use in single contrast radiographic examinations of the esophagus, stomach, duodenum and small bowel to visualize the gastrointestinal tract in... Read More
Voyageur Pharmaceuticals Ltd. ( TSX.V : VM ) USA (OTC : VYYRF) (the "Company" or "Voyageur") announces that it has signed a cost plus manufacturing agreement with Alberta Veterinarian Laboratories Ltd. ("AVL"). This agreement allows Voyageur to begin the process of formulating and testing our new products with AVL and prepare for production and sales. AVL is committing mixing and fill lines for Voyageur's production.... Read More
Voyageur Pharmaceuticals Ltd. ( TSXV : VM ) ( OTC : VYYRF) (the "Company" or "Voyageur") announces that it has received $ 209,764.05 in cash proceeds from the exercise of previously issued warrants, finder's warrants and stock options. The proceeds will be allocated to continue to move the Company forward towards cash flow. Brent Willis, CEO of Voyageur, states “We are very appreciative to all the shareholders who continue... Read More
Voyageur Pharmaceuticals Ltd. ( TSX V : VM ) ( OTC : VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada for its second product, HDX Ba . HDX Ba is a barium radiographic contrast powder for suspension that is specifically formulated for Fluoroscopy barium X-Ray procedures and can also be used for CT Scans. This approval authorizes the sale of HDX Ba for use in... Read More
Voyageur Pharmaceuticals Ltd. ( TSXV : VM ) USA (OTC : VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada for SmoothX. SmoothX is a barium radiographic contrast suspension that is specifically formulated for computed tomography procedures (CT Scans). This approval authorizes the sale of SmoothX for use in radiology procedures in Canada. SmoothX is specifically... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS